Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: ReShape Lifesciences

Market Cap 15.23M 13.27M 12.23M 11.51M 21.53M 1.44B 21.68M 146M 56.52M 707M 57.17M 55.94M 2.45B P/E 2026 *
-3.08x
P/E 2027 * -2.37x
Enterprise Value 15.23M 13.27M 12.23M 11.51M 21.53M 1.44B 21.68M 146M 56.52M 707M 57.17M 55.94M 2.45B EV / Sales 2026 *
102x
EV / Sales 2027 * 60.9x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -

Financials

2026 *2027 *
Net sales 150K 131K 120K 113K 212K 14.14M 213K 1.43M 557K 6.97M 563K 551K 24.15M 250K 218K 201K 189K 353K 23.56M 356K 2.39M 928K 11.61M 938K 918K 40.25M
Net income -4.89M -4.26M -3.93M -3.69M -6.91M -461M -6.96M -46.73M -18.15M -227M -18.35M -17.96M -787M -7.77M -6.77M -6.24M -5.87M -10.98M -732M -11.06M -74.24M -28.83M -361M -29.16M -28.54M -1.25B
Net Debt - -
Logo ReShape Lifesciences
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
Employees
-
Sector
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!